Medical/Pharmaceuticals

LTS Expands CDMO Portfolio with Ophthalmic Drug Delivery Solutions

ANDERNACH, Germany, April 29, 2026 /PRNewswire/ -- LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company specializing in advanced drug delivery systems, today announced the expansion of its service portfolio to include CDMO services for ophthalmic drug delivery solu...

2026-04-29 19:00 3324

ESG | HitGen Releases 2025 Sustainability Report

CHENGDU, China, April 29, 2026 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) released its 2025 Sustainability Report on April 29, 2026. This report is the second sustainability report of HitGen, aiming to present the Company's philosophies and polic...

2026-04-29 19:00 3769

China's Yangtze River Pharmaceutical Group Expands Global Footprint as Quality Drives Growth

TAIZHOU, China, April 29, 2026 /PRNewswire/ -- In 2025, Yangtze River Pharmaceutical Group (YRPG) made significant progress in both global growth and quality initiatives. The company's international revenue increased more than fourfold year over year, while the number of its global partners more ...

2026-04-29 18:57 2600

European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe

SHANGHAI, April 29, 2026 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar ...

2026-04-29 18:08 3578

INTCO Medical Reports 2025 Results with Resilient Growth, Revenue Reaches Four-Year High as Industry Rebalances

ZIBO, China, April 29, 2026 /PRNewswire/ -- INTCO Medical ("INTCO" or "the Company"), a leading global manufacturer of disposable gloves, reported its 2025 annual results, with revenue reaching RMB 9.93 billion (approximately US$1.46 billion), up 4.23% year over y...

2026-04-29 17:07 4959

State Grid Changzhou Power Pioneers Drone-Based Ultraviolet Imaging Technology for Precision Power Line Fault Detection

CHANGZHOU, China, April 29, 2026 /PRNewswire/ -- State Grid Changzhou Power Supply Company has deployed drone-based ultraviolet (UV) imaging technology for the first time to enable precision inspection of distribution lines in Liyang, Changzhou. The new technical solution supports early detection...

2026-04-29 17:04 3639

WHX Bangkok and Medtec Southeast Asia 2026 to Position Thailand as the Gateway to ASEAN's Medical Market

BANGKOK, April 29, 2026 /PRNewswire/ -- From 8 to 10 July, Informa Markets will take the global stage, uniting over 950 exhibitors at International Healthcare Week and reinforcing Thailand's leadership in healthcare and medical manufacturing. The event will feature two major co-located exhibit...

2026-04-29 14:02 4128

ABC Impact Releases 2025 Impact Review

SINGAPORE, April 29, 2026 /PRNewswire/ -- ABC Impact, the Singapore-based Asia-focused impact investment firm, has published its 2025 Impact Review, available atwww.abcimpact.com.sg . The review covers the firm's investment and impact activity across its two funds ov...

2026-04-29 11:00 3344

Alma Unveils Longevity Approach at Alma Academy, Advancing Long-Term Skin Performance

CAESAREA, Israel, April 29, 2026 /PRNewswire/ -- Alma , a Sisram Medical company and a global leader in medical aesthetic solutions, unveiled its longevity strategy at its global Alma Academy, outlining its shift toward a continuous care model and a new long-term growth a...

2026-04-29 09:30 3562

Insilico's Rentosertib Inhalation Solution Receives IND Clearance for the World's First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study

* Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received IND clearance from the CDE. * The inhalation solution is designed for targeted lung delivery...

2026-04-29 09:00 4318

Alma Unveils Longevity Approach at Alma Academy, Advancing Long-Term Skin Performance

CAESAREA, Israel, April 29, 2026 /PRNewswire/ -- Alma , a Sisram Medical company and a global leader in medical aesthetic solutions, unveiled its longevity strategy at its global Alma Academy, outlining its shift toward a continuous care model and a new long-term growth a...

2026-04-29 08:30 3175

Piramal Pharma Limited Announces Results for Q4 and Full-year FY26

MUMBAI, India, April 28, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full-year ended 31st March 2026. Consolidated...

2026-04-29 03:51 4368

ACROBiosystems Wins CiteAb Award, Gaining Worldwide Recognition

SAN DIEGO and NEWARK, Del., April 28, 2026 /PRNewswire/ -- Recently, ACROBiosystems was honored as a "Protein Supplier to Watch in Cancer Research in 2026" at the CiteAb Awards. CiteAb accelerates scientific research by providing a search engine and data services, and its awards leverage high-qu...

2026-04-28 23:00 4014

Natural Field Releases Research Findings on NFTriSolve® Co-Loading Liposome Formula

XI'AN, China, April 28, 2026 /PRNewswire/ -- Natural Field announced that the latest research and development breakthrough of the NFTriSolve® co-loading liposome technology has been achieved. Through a comparison of different formulations and processes in a zebrafish experiment, the research resu...

2026-04-28 22:59 4608

Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution

SHANGHAI, April 28, 2026 /PRNewswire/ -- On 28 April, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its results for the first quarter of 2026 (the reporting period). During the reporting period, the Company achieved a total revenue of RMB 10,073 million, representing a ...

2026-04-28 22:54 6421

The Benefits of Prostate Cancer Screening Outweigh the Harms, According to New Patient Guidelines From NCCN

Free, comprehensive guidebook shows how prostate cancer screening has largely deemphasized invasive testing in order to avoid unnecessary procedures and treatment while at the same time saving lives. PLYMOUTH MEETING, Pa., April 28, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network®...

2026-04-28 22:04 4559

ACROBiosystems Showcases AI-Driven Innovation at AACR 2026, Empowering Next-Generation Biologics Discovery

SAN DIEGO and NEWARK, N.J., April 28, 2026 /PRNewswire/ -- From April 17 to 22, 2026, ACROBiosystems—a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries—presented its comprehensive, AI‑driven protein solutions at the American Association for Cancer...

2026-04-28 22:00 5069

C-Ray Therapeutics Receives FDA Acceptance of Type II Drug Master File for Copper-64 (Cu-64)

DMF No. 43568 is now active and available for reference in global IND and NDA submissions CHENGDU, China, April 28, 2026 /PRNewswire/ -- C-Ray Therapeutics (Chengdu) Co., Ltd., today announced that its Type II Drug Master File (DMF) for COPPER [64Cu] CHLORIDE FOR RADIOLABELLING has been listed a...

2026-04-28 21:11 2930

Nuevocor Appoints Dr. Monica Shah as Chief Medical Officer

SINGAPORE, PARIS and PHILADELPHIA, April 28, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company developing novel therapies for patients suffering from life-threatening cardiomyopathies, today announced the appointment of Monica Shah, MD, FACC, as Chief Medical Officer. Dr. Shah...

2026-04-28 21:05 3754

World's First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceutical

CHONGQING, China, April 28, 2026 /PRNewswire/ -- Chongqing Claruvis Pharmaceutical Co., Ltd. recently announced that the China's National Medical Products Administration (NMPA) has approved its Retoxin® (recombinant botulinum toxin type A, project code YY001) for the temporary improvement of mod...

2026-04-28 20:38 3767
1 ... 16171819202122 ... 650